Insight

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman/X

Oct 22, 2024, 14:57

Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy

Joseph Grossman, Vice President of Early Clinical Development at Agenus, shared a post on LinkedIn:

“The final version of our recent Cancer Discovery paper came out today “Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy”.
I couldn’t be prouder of our team at Agenus, or more excited for the future of oncology.”

Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Authors: Dhan Chand, et al.

Joseph Grossman

AACR Agenus cancer cancer awareness cancer care Cancer Discovery Dhan Chand fight against cancer Global fight against cancer immunotherapy Joseph Grossman OncoDaily Oncology

Bernard Fox received SITC lifetime achievement award

Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Special Coverage